Intellia is a genome editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. This technology offers the potential to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. Intellia's combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

TypePublic
HQCambridge, US
Founded2014
Size (employees)104 (est)+71%
Websiteintelliatx.com
Intellia Therapeutics was founded in 2014 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Intellia Therapeutics

Nessan Bermingham

Nessan Bermingham

Co-Founder

Intellia Therapeutics Office Locations

Intellia Therapeutics has an office in Cambridge
Cambridge, US (HQ)
40 Erie St Ste 130
Show all (1)
Report incorrect company information

Intellia Therapeutics Financials and Metrics

Intellia Therapeutics Revenue

USD

Net income (Q1, 2018)

(21.4 m)

EBIT (Q1, 2018)

(22.4 m)

Market capitalization (20-Sep-2018)

1.4 b

Closing stock price (20-Sep-2018)

31.5

Cash (31-Mar-2018)

327.8 m
Intellia Therapeutics's current market capitalization is $1.4 b.
Annual
USDFY, 2016

General and administrative expense

5.1 b

R&D expense

11.3 b

Operating expense total

16.4 b

EBIT

(10.8 b)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

3.2 m3.7 b4.7 b5.7 m6.4 m7.4 m

R&D expense

5.2 m7.4 b7.9 b13.4 m15.6 m22.5 m

Operating expense total

8.5 m11.2 b12.6 b19.2 m21.9 m29.9 m

EBIT

(6.7 m)(6.9 b)(7.7 b)(12.9 m)(16 m)(22.4 m)
Annual
USDFY, 2016

Cash

273.1 m

Accounts Receivable

6.5 m

Inventories

1.8 m

Current Assets

281.3 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

64.2 m300.7 m290.6 m257.6 m241 m327.8 m

Accounts Receivable

1 m1 m1.1 m2.4 m2.8 m7.5 m

Current Assets

65.9 m302.9 m292.7 m261.1 m245.9 m337.7 m

PP&E

4.2 m4.4 m5.5 m11.4 m12.6 m16 m
Annual
USDFY, 2016

Net Income

(10.6 b)

Depreciation and Amortization

3 k

Inventories

(285 k)

Accounts Payable

163 k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(6.7 m)(13.6 m)(21.1 m)(12.6 m)(28.2 m)(21.4 m)

Depreciation and Amortization

187 k434 k699 k660 k1.4 m1 m

Accounts Payable

(87 k)(367 k)154 k(954 k)(670 k)59 k

Cash From Operating Activities

(9.4 m)58.1 m50.5 m(11.4 m)(27.1 m)(17.8 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Intellia Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Intellia Therapeutics News and Updates

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

ZUG, Switzerland and CAMBRIDGE, Mass. and BERKELEY, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Caribou Biosciences, Inc. announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) affi…

Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution

  Robust, dose-responsive liver editing and reduction of TTR protein shown  in humanized mouse model

Intellia Therapeutics Announces Second Quarter 2018 Financial Results

CAMBRIDGE, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced financial results and operational progress for the second quarter of 2018.
Report incorrect company information

Intellia Therapeutics Company Life and Culture

Report incorrect company information